<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643535</url>
  </required_header>
  <id_info>
    <org_study_id>2020/202/OB</org_study_id>
    <nct_id>NCT04643535</nct_id>
  </id_info>
  <brief_title>In Vivo Glycocalyx as Predictor of Complications After Cardiac Surgery</brief_title>
  <acronym>GLYPOCS</acronym>
  <official_title>Glycocalyx as Predictor of Complications After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac surgery has been described as altering endothelium structure and function, notably&#xD;
      because of the use of cardiac-pulmonary bypass (CPB). Among the endothelial structure,&#xD;
      glycocalyx, the thin layer recovering the endothelial surface, may be altered by the&#xD;
      inflammatory process and probably the modification of flow during CPB. Endothelial and&#xD;
      glycocalyx integrity are essential for vascular function and glycocalyx destruction is&#xD;
      associated with organ failure and mortality. On the other hand, a chronic alteration of&#xD;
      glycocalyx is observed in many diseases such as diabetes, hypertension or chronic kidney&#xD;
      failure, all pathologies frequently observed in patients benefiting grom cardiac surgery.&#xD;
&#xD;
      Thus the preoperative alteration of glycocalyx may be associated with postoperative organ&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>association between preoperative sublingual glycocalyx thickness (glycocheck device) and major postoperative complications</measure>
    <time_frame>48 hours</time_frame>
    <description>occurence within 48 postoperative hours of at least one item among:&#xD;
vasoplegic shock&#xD;
cardiogenic shock&#xD;
prolonged mechanical ventilation&#xD;
acute kidney failure&#xD;
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>association between preoperative sublingual glycocalyx thickness (glycocheck device) and death</measure>
    <time_frame>28 days</time_frame>
    <description>death from any causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>association between preoperative sublingual glycocalyx thickness (glycocheck device) and cardiac arrythmia</measure>
    <time_frame>28 days</time_frame>
    <description>atrial or ventricular arrythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>association between preoperative sublingual glycocalyx thickness (glycocheck device) and Cerebral stroke</measure>
    <time_frame>28 days</time_frame>
    <description>ischemic of hemorrhagic etiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>association between preoperative sublingual glycocalyx thickness (glycocheck device) and cognitive dysfunction</measure>
    <time_frame>28 days</time_frame>
    <description>delirium or alteration of cognitive status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>association between preoperative sublingual glycocalyx thickness (glycocheck device) and myocardial ischemia</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of ischemia: new Q wave, new occlusion of a coronary arteria, elevated troponinemia with a new dysfunction of at least one myocardial segment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>association between preoperative sublingual glycocalyx thickness (glycocheck device) and acute respiratory failure</measure>
    <time_frame>28 days</time_frame>
    <description>need for at least 5L/min of oxygen or non invasive ventilation of reintubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>association between preoperative sublingual glycocalyx thickness (glycocheck device) and sepsis</measure>
    <time_frame>28 days</time_frame>
    <description>new sepsis condition as defined by SEPSIS-3 definition</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Surgery</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients benefiting from cardiac surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all patients benefiting from a cardiac surgery with cardio-pulmonary bypass&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  impossibility to carry out the measurement by glycocheck device&#xD;
&#xD;
          -  refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emmanuel Besnier, MD PhD</last_name>
    <phone>+33232881705</phone>
    <email>emmanuel.besnier@chu-rouen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>emmanuel besnier, MD</last_name>
      <phone>+33 2 32 88 17 05</phone>
      <email>emmanuel.besnier@chu-rouen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

